TD Cowen Begins Coverage on Centessa Pharmaceuticals (NASDAQ:CNTA)

TD Cowen initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) in a report issued on Tuesday, Marketbeat reports. The firm set a "buy" rating on the stock.

Other research analysts have also issued reports about the company. B. Riley started coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a "buy" rating and a $33.00 price objective for the company. Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. BMO Capital Markets upped their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a research report on Monday, September 16th. Guggenheim lifted their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group upped their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $25.83.

Centessa Pharmaceuticals Trading Up 3.5 %

Centessa Pharmaceuticals stock traded up $0.58 during trading on Tuesday, reaching $17.32. 666,884 shares of the company were exchanged, compared to its average volume of 521,046. The stock's 50 day simple moving average is $16.93 and its two-hundred day simple moving average is $14.30. The company has a market capitalization of $2.28 billion, a P/E ratio of -11.32 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals has a 52-week low of $6.65 and a 52-week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. On average, equities research analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other news, General Counsel Iqbal J. Hussain sold 77,705 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $16.39, for a total value of $1,273,584.95. Following the completion of the transaction, the general counsel now owns 125,785 shares in the company, valued at approximately $2,061,616.15. This trade represents a 38.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 2,592 shares of the company's stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44. Following the sale, the chief executive officer now owns 630,661 shares in the company, valued at $9,661,726.52. The trade was a 0.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 368,023 shares of company stock worth $6,335,574. Corporate insiders own 11.59% of the company's stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of large investors have recently modified their holdings of CNTA. First Light Asset Management LLC grew its stake in shares of Centessa Pharmaceuticals by 59.2% during the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock worth $43,168,000 after purchasing an additional 1,778,515 shares in the last quarter. Perceptive Advisors LLC boosted its position in shares of Centessa Pharmaceuticals by 27.6% during the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company's stock worth $35,518,000 after acquiring an additional 850,000 shares in the last quarter. FMR LLC increased its holdings in shares of Centessa Pharmaceuticals by 4.6% in the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company's stock valued at $46,635,000 after acquiring an additional 129,300 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Centessa Pharmaceuticals by 54.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company's stock worth $43,423,000 after acquiring an additional 953,659 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock worth $38,360,000 after purchasing an additional 1,145,823 shares during the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.